{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:39:51Z","timestamp":1792629591464,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"\n Abstract<\/jats:title>\n \n The purpose of this study is to evaluate the efficacy and safety of belimumab combined with the standard regimen in treating children with active lupus nephritis. This single-center, retrospective cohort study used clinical data of children with newly active lupus nephritis hospitalized in the Department of Nephrology between December 2004 and February 2023. Patients were divided into a belimumab or traditional treatment group according to whether or not they received belimumab. Renal remission and recurrence rates and glucocorticoid dose were compared between groups. Forty-seven children (median age 11\u00a0years) were enrolled, including 30 and 17 children in the traditional treatment and belimumab groups, respectively. The Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2000) score of children in the belimumab group (23.59\u2009\u00b1\u20097.78) was higher than that in the traditional treatment group (19.13\u2009\u00b1\u20096.10) (\n P<\/jats:italic>\n \u2009=\u20090.035). The two groups showed no significant difference in the frequency of pyuria, gross hematuria, and the levels of 24-h proteinuria and estimated glomerular filtration rate. The complement C3\/C4 in the belimumab group recovered faster than that in the traditional treatment group (\n P<\/jats:italic>\n \u2009<\u20090.05). There were no between-group differences in the complete renal remission rate at 6 or 12\u00a0months (\n P<\/jats:italic>\n \u2009=\u20090.442,\n P<\/jats:italic>\n \u2009=\u20090.759). There were no between-group differences in 1-year recurrence rate (\n P<\/jats:italic>\n \u2009=\u20090.303). Furthermore, 6 and 12\u00a0months after treatment, glucocorticoid doses were lower in the belimumab than the traditional treatment group (17.87\u2009\u00b1\u20096.96\u00a0mg\/d vs. 27.33\u2009\u00b1\u20098.40\u00a0mg\/d,\n P<\/jats:italic>\n \u2009=\u20090.000; 10.00 (5.3) mg\/d vs. 13.75 (10.0) mg\/d,\n P<\/jats:italic>\n \u2009=\u20090.007), respectively.\n <\/jats:p>\n <\/jats:sec>\n \n \n Conclusion<\/jats:italic>\n <\/jats:title>\n With an equivalent renal remission rate, belimumab combined with the standard traditional regimen might promote the tapering of glucocorticoids, and the incidence of adverse events is low.<\/jats:p>\n \n \n \n \n \n \n What is known<\/jats:bold>\n :\n <\/jats:td>\n <\/jats:tr>\n \n \n \u2022\n Belimumab is documented as an adjunctive treatment with systemic lupus erythematosus (c-SLE) LN with efficacy.<\/jats:italic>\n \u2022\n Due to the paucity of studies, its effects and side effects in children with LN remain unclear.<\/jats:italic>\n <\/jats:td>\n <\/jats:tr>\n \n \n What is new<\/jats:bold>\n :\n <\/jats:td>\n <\/jats:tr>\n \n \n \u2022\n This single-center, retrospective cohort study evaluated the efficacy and safety of belimumab combined with the standard regimen in treating children with proliferative LN.<\/jats:italic>\n \u2022\n Belimumab combined with the standard traditional treatment might promote the tapering of glucocorticoids, while exhibiting a low occurrence of adverse events.<\/jats:italic>\n <\/jats:td>\n <\/jats:tr>\n <\/jats:tbody>\n <\/jats:table>\n <\/jats:table-wrap>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00431-024-05662-9","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T12:55:15Z","timestamp":1719579315000},"page":"3987-3995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis"],"prefix":"10.1007","volume":"183","author":[{"given":"Huarong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"5662_CR1","doi-asserted-by":"publisher","first-page":"1128754","DOI":"10.3389\/fimmu.2023.1128754","volume":"14","author":"L Pan","year":"2023","unstructured":"Pan L, Liu J, Liu C et al (2023) Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy. Front Immunol 14:1128754. https:\/\/doi.org\/10.3389\/fimmu.2023.1128754","journal-title":"Front Immunol"},{"key":"5662_CR2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00467-020-04686-1","volume":"36","author":"L Oni","year":"2021","unstructured":"Oni L, Wright RD, Marks S, Beresford MW, Tullus K (2021) Kidney outcomes for children with lupus nephritis. Pediatr Nephrol 36:1377\u20131385. https:\/\/doi.org\/10.1007\/s00467-020-04686-1","journal-title":"Pediatr Nephrol"},{"key":"5662_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2215\/CJN.07810621","volume":"17","author":"SE Wenderfer","year":"2022","unstructured":"Wenderfer SE, Chang JC, Goodwin Davies A et al (2022) Using a multi-institutional pediatric learning health system to identify systemic lupus erythematosus and lupus nephritis: development and validation of computable phenotypes. Clin J Am Soc Nephrol 17:65\u201374. https:\/\/doi.org\/10.2215\/CJN.07810621","journal-title":"Clin J Am Soc Nephrol"},{"key":"5662_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","volume":"47","author":"SP Canny","year":"2021","unstructured":"Canny SP, Jackson SW (2021) B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies. Rheum Dis Clin North Am 47:395\u2013413. https:\/\/doi.org\/10.1016\/j.rdc.2021.04.006","journal-title":"Rheum Dis Clin North Am"},{"key":"5662_CR5","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151\u20131159. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214819","journal-title":"Ann Rheum Dis"},{"key":"5662_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/ndt\/gfab152","volume":"37","author":"S Demir","year":"2022","unstructured":"Demir S, G\u00fclhan B, \u00d6zen S et al (2022) Long-term renal survival of paediatric patients with lupus nephritis. Nephrol Dial Transplant 37:1069\u20131077. https:\/\/doi.org\/10.1093\/ndt\/gfab152","journal-title":"Nephrol Dial Transplant"},{"key":"5662_CR7","doi-asserted-by":"publisher","first-page":"108274","DOI":"10.1016\/j.clim.2019.108274","volume":"209","author":"EMD Smith","year":"2019","unstructured":"Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM (2019) Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol 209:108274. https:\/\/doi.org\/10.1016\/j.clim.2019.108274","journal-title":"Clin Immunol"},{"key":"5662_CR8","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1681\/ASN.2016040415","volume":"27","author":"SV Parikh","year":"2016","unstructured":"Parikh SV, Rovin BH (2016) Current and emerging therapies for lupus nephritis. J Am Soc Nephrol 27:2929\u20132939. https:\/\/doi.org\/10.1681\/ASN.2016040415","journal-title":"J Am Soc Nephrol"},{"key":"5662_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/0961203312474084","volume":"22","author":"M Hui","year":"2013","unstructured":"Hui M, Garner R, Rees F et al (2013) Lupus nephritis: a 15-year multi-centre experience in the UK. Lupus 22:328\u2013332. https:\/\/doi.org\/10.1177\/0961203312474084","journal-title":"Lupus"},{"key":"5662_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/OARRR.S166303","volume":"11","author":"JH Yo","year":"2019","unstructured":"Yo JH, Barbour TD, Nicholls K (2019) Management of refractory lupus nephritis: challenges and solutions. Open Access Rheumatol 11:179\u2013188. https:\/\/doi.org\/10.2147\/OARRR.S166303","journal-title":"Open Access Rheumatol"},{"key":"5662_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13075-016-1202-z","volume":"19","author":"H Hanaoka","year":"2017","unstructured":"Hanaoka H, Yamada H, Kiyokawa T et al (2017) Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV(J). Arthritis Res Ther 19:4. https:\/\/doi.org\/10.1186\/s13075-016-1202-z","journal-title":"Arthritis Res Ther"},{"key":"5662_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ekir.2022.10.014","volume":"8","author":"EYH Chan","year":"2023","unstructured":"Chan EYH, Yap DYH, Wong WT et al (2023) Long-term outcomes of children and adolescents with biopsy-proven childhood-onset lupus nephritis. Kidney Int Rep 8:141\u2013150. https:\/\/doi.org\/10.1016\/j.ekir.2022.10.014","journal-title":"Kidney Int Rep"},{"key":"5662_CR13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1136\/annrheumdis-2016-210960","volume":"76","author":"N Groot","year":"2017","unstructured":"Groot N, de Graeff N, Avcin T et al (2017) European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 76:1788\u20131796. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210960","journal-title":"Ann Rheum Dis"},{"key":"5662_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00467-022-05670-7","volume":"38","author":"M Kaneko","year":"2023","unstructured":"Kaneko M, Jackson SW (2023) Recent advances in immunotherapies for lupus nephritis. Pediatr Nephrol 38:1001\u20131012. https:\/\/doi.org\/10.1007\/s00467-022-05670-7","journal-title":"Pediatr Nephrol"},{"key":"5662_CR15","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00467-022-05811-y","volume":"38","author":"AP Sakamoto","year":"2023","unstructured":"Sakamoto AP, Silva CA, Islab\u00e3o AG et al (2023) Chronic kidney disease in patients with childhood-onset systemic lupus erythematosus. Pediatr Nephrol 38:1843\u20131854. https:\/\/doi.org\/10.1007\/s00467-022-05811-y","journal-title":"Pediatr Nephrol"},{"key":"5662_CR16","doi-asserted-by":"publisher","first-page":"kead447","DOI":"10.1093\/rheumatology\/kead447","volume":"26","author":"EY Chan","year":"2023","unstructured":"Chan EY, Yap DY, Wong WH et al (2023) Renal relapse in children and adolescents with childhood-onset lupus nephritis: a 20-year study. Rheumatol (Oxf Engl) 26:kead447. https:\/\/doi.org\/10.1093\/rheumatology\/kead447","journal-title":"Rheumatol (Oxf Engl)"},{"key":"5662_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/pediatric14020030","volume":"14","author":"SE Wenderfer","year":"2022","unstructured":"Wenderfer SE, Orjuela A, Bekheirnia MR et al (2022) Lupus nephritis, autoantibody production and kidney outcomes in males with childhood-onset systemic lupus erythematosus. Pediatr Rep 14:220\u2013232. https:\/\/doi.org\/10.3390\/pediatric14020030","journal-title":"Pediatr Rep"},{"key":"5662_CR18","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s10067-019-04631-0","volume":"38","author":"FJ Fiorot","year":"2019","unstructured":"Fiorot FJ, Islab\u00e3o AG, Pereira RM et al (2019) Disease presentation of 1312 childhood-onset systemic lupus erythematosus: influence of ethnicity. Clin Rheumatol 38:2857\u20132863. https:\/\/doi.org\/10.1007\/s10067-019-04631-0","journal-title":"Clin Rheumatol"},{"key":"5662_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.semarthrit.2019.05.010","volume":"49","author":"M Heshin-Bekenstein","year":"2019","unstructured":"Heshin-Bekenstein M, Trupin L, Yelin E et al (2019) Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 49:267\u2013272. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.05.010","journal-title":"Semin Arthritis Rheum"},{"key":"5662_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"key":"5662_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","volume":"81","author":"X Yu","year":"2023","unstructured":"Yu X, Chen N, Xue J et al (2023) Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population. Am J Kidney Dis 81:294-306.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2022.06.013","journal-title":"Am J Kidney Dis"},{"key":"5662_CR22","doi-asserted-by":"publisher","first-page":"e001747","DOI":"10.1136\/rmdopen-2021-001747","volume":"7","author":"HI Brunner","year":"2021","unstructured":"Brunner HI, Abud-Mendoza C, Mori M et al (2021) Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open 7:e001747. https:\/\/doi.org\/10.1136\/rmdopen-2021-001747","journal-title":"RMD Open"},{"key":"5662_CR23","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO et al (2020) Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 79:1340\u20131348. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217101","journal-title":"Ann Rheum Dis"},{"key":"5662_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40744-022-00454-9","volume":"9","author":"SP Huang","year":"2022","unstructured":"Huang SP, Snedecor SJ, Nanji S, Lloyd E, Bell CF (2022) Real-world effectiveness of belimumab in systemic lupus erythematosus: a systematic literature review. Rheumatol Ther 9:975\u2013991. https:\/\/doi.org\/10.1007\/s40744-022-00454-9","journal-title":"Rheumatol Ther"},{"key":"5662_CR25","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/art.40861","volume":"71","author":"DJ Wallace","year":"2019","unstructured":"Wallace DJ, Ginzler EM, Merrill JT et al (2019) Safety and efficacy of belimumab plus standard therapy for UP to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol 71:1125\u20131134. https:\/\/doi.org\/10.1002\/art.40861","journal-title":"Arthritis Rheumatol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-024-05662-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T06:07:29Z","timestamp":1723529249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-024-05662-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["5662"],"URL":"https:\/\/doi.org\/10.1007\/s00431-024-05662-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4199333\/v1","asserted-by":"object"}]},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"1 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Children\u2019s Hospital Affiliated to Beijing Capital Pediatric Research Institute in China (SHERLL2021052).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from parents and participants in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}